HUDSON, Mass.--(

哈得逊，马萨诸塞州--(

BUSINESS WIRE

商业热线

)--Katahdin Industries, LLC is pleased to announce the sale of substantially all of the assets of Precision Coating to Integer Holdings Corporation. The transaction closed on January 7, 2025. Precision Coating provides global Medtech customers with innovative products and services to enhance the surface functionality of patient-critical products..

)--Katahdin Industries，LLC很高兴宣布将精密涂料的大部分资产出售给Integer Holdings Corporation。交易于2025年1月7日结束。精密涂层为全球Medtech客户提供创新产品和服务，以增强患者关键产品的表面功能。。

Since 2006, Precision Coating has built a highly specialized proprietary coatings platform in the medical technology supply chain. The portfolio build, positioning and growth trajectory was accelerated through five acquisitions including CHN Metal Finishing (2008), Medi-Solve (2008), Boyd Coatings Research (2015), a merger with N2 Biomedical (2021), and Providence Texture (2023).

自2006年以来，精密涂料在医疗技术供应链中建立了高度专业化的专有涂料平台。通过五次收购，包括CHN Metal Finishing（2008年）、Medi Solve（2008年）、Boyd Coatics Research（2015年）、与N2 Biomedical（2021年）和Providence Texture（2023年）的合并，加快了投资组合的构建、定位和增长轨迹。

A nearly ten-fold increase in scale over the hold period was further facilitated by investments in data systems, automation, materials development, and greenfield expansion in Costa Rica. The company currently operates out of four North American sites and one in Costa Rica..

。该公司目前在四个北美地区运营，一个在哥斯达黎加运营。。

“From the very beginning, we identified precise control over surface treatment as a key feature in the medical device manufacturing process,” commented Tim Cabot, Chairman of Katahdin. “We also saw a gap in the market to address unique coating-as-a-service needs for medical device customers and to position the company to become a fully capable contract manufacturing services provider for the full life cycle of each product we work on.

Katahdin董事长蒂姆·卡博特（TimCabot）评论道：“从一开始，我们就将表面处理的精确控制确定为医疗器械制造过程中的一个关键特征。“我们还看到了市场上的差距，以满足医疗器械客户独特的涂层即服务需求，并将公司定位为在我们所从事的每种产品的整个生命周期内完全有能力的合同制造服务提供商。

Over time our market focus has also allowed us to expand and enhance our specialized, high-value, and innovative application solutions, including GlideLine™, our proprietary fluoropolymer coatings for medical devices; MICRALOX®, our patented anodic coatings for re-usable medical instruments; and IonGuard®, our proprietary ion treatment for implants.”.

随着时间的推移，我们的市场焦点也使我们能够扩大和增强我们的专业化，高价值和创新的应用解决方案，包括GlideLine™，我们专有的医疗器械氟聚合物涂料；MICRALOX®，我们的专利阳极涂层，用于可重复使用的医疗器械；和IonGuard®，我们专有的植入物离子治疗。”。

Bill Ellerkamp, President of Precision Coating, added, “We are very excited about the acquisition of Precision Coating by Integer. We are proud of the strong and defensible position we’ve built in the proprietary coatings segment of the Medtech industry and the exceptional company culture we’ve created.

精密涂料总裁比尔·埃勒坎普（BillEllerkamp）补充道：“我们对Integer收购精密涂料感到非常兴奋。我们为我们在医疗技术行业专有涂料领域建立的强大防御地位以及我们创造的卓越公司文化感到骄傲。

Integer is uniquely positioned to capitalize on the strengths of our technologies and our respective cultures are well aligned. We are confident in the future of Precision Coating as part of Integer.”.

Integer的独特定位是利用我们技术的优势，我们各自的文化也很好地协调一致。作为Integer的一部分，我们对精密涂层的未来充满信心。”。

Piper Sandler & Co. served as exclusive financial advisor to Katahdin and Ruberto, Israel, & Weiner, P.C. served as legal advisors.

。

About Katahdin

关于Katahdin

Katahdin Industries, LLC is a closely held investment corporation with both individual and institutional ownership. Following Katahdin’s 2021 merger with N2 Biomedical, Ampersand Capital Partners became a minority shareholder and provided strategic guidance cultivated from a deep history of investing in medical contract design and manufacturing organizations.

Katahdin Industries，LLC是一家拥有个人和机构所有权的封闭式投资公司。卡塔赫丁于2021年与N2 Biomedical合并后，安培生资本合伙人成为少数股东，并提供了从投资医疗合同设计和制造组织的悠久历史中培养出来的战略指导。

Tim Cabot and Bob DeAngelis led the original acquisition and company build out through 2018 when Bill Ellerkamp became President of Precision Coating. Additional information about Precision Coating is available at .

蒂姆·卡博特（TimCabot）和鲍勃·迪恩盖利斯（BobDeAngelis）领导了最初的收购，并在2018年比尔·埃勒坎普（BillEllerkamp）担任精密涂层总裁时完成了公司的扩建。有关精密涂层的其他信息，请访问。

www.precisioncoating.com

www.precisioncoating.com

.

.

About Ampersand Capital Partners

关于Ampersand Capital Partners

Founded in 1988, Ampersand Capital Partners is a middle market private equity firm with $3 billion of assets under management dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive long-term performance alongside its portfolio company management teams.

安倍资本合伙公司成立于1988年，是一家中等市场私人股本公司，管理着30亿美元的资产，致力于医疗保健领域的增长型投资。安倍在马萨诸塞州波士顿和荷兰阿姆斯特丹设有办事处，利用私募股权和运营经验的独特融合，与投资组合公司管理团队一起创造价值并推动长期业绩。

Ampersand has helped build numerous market-leading companies across each of the firm’s core healthcare sectors. For additional information, visit .

Ampersand帮助在公司的每个核心医疗保健部门建立了众多市场领先的公司。有关更多信息，请访问。

www.ampersandcapital.com

www.ampersandcapital.com

or follow us on

或者继续关注我们

LinkedIn

LinkedIn

.

.

About Integer

关于整数

®

®

Integer Holdings Corporation (NYSE: ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets. As a strategic partner of choice to medical device companies and OEMs, the Company is committed to enhancing the lives of patients worldwide by providing innovative, high-quality products and solutions.

Integer Holdings Corporation（纽约证券交易所：ITGR）是世界上最大的医疗器械合同开发和制造组织（CDMO）之一，服务于心律管理，神经调节以及心脏和血管市场。作为医疗器械公司和OEM首选的战略合作伙伴，该公司致力于通过提供创新、高质量的产品和解决方案来改善全球患者的生活。

The Company's brands include Greatbatch Medical® and Lake Region Medical®. Additional information is available at .

该公司的品牌包括Greatbatch Medical®和Lake Region Medical®。有关其他信息，请访问。

www.integer.net

www.integer.net